Abstract
The anti-OKT3 response was studied in 40 paediatric kidney transplant recipients receiving OTK3 as a prophylactic treatment in association with azathioprine and prednisone. Only 1 patient experienced a reversible acute rejection episode while receiving OKT3. OKT3 induced a rapid disappearance of CD3+ cells, but significant proportions of CD3+ cells reappeared before the end of the treatment in 14 patients. Wide variations in circulating OKT3 levels were observed and in only 50% of patients could stable circulating OKT3 levels be detected until discontinuation of treatment. Anti-OKT3 antibodies detected by the enzyme-linked immunosorbent assay (ELISA) (anti-idiotypic and anti-isotypic antibodies) developed in 91% of patients. Anti-idiotypic antibodies detected by the immunofluorescence inhibition test were found in the sera of 71% of patients, always when high titres of anti-OKT3 antibodies were detected by ELISA. As it has recently been shown that anti-idiotypic antibodies are associated with failure of subsequent OKT3 treatment, we conclude that OKT3 should be restricted to steroid-resistant rejection crises in paediatric patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Norman DJ, Shield CF, Barry JM (1987) Therapeutic use of OKT3 monoclonal antibody for acute renal allograft rejection. Nephron 46: 41–47
Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, Laquaglia MP, Tolkoff-Rubin N, Rubin RH, Herrin JT, Russel PS (1981) Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32: 535–539
Costanzo-Nordin MR, Silver MA, O'Connell JB (1987) Successful reversal of acute cardiac allograft rejection with OKT3 monoclonal antibody. Circulation 76: 71–80
Fung JJ, Markus BH, Gordon RD, Esquivel CO, Makowka L, Tzakis AG, Starzl TE (1987) Impact of Orthoclone OKT3 on liver transplantation. Transplant Proc 19: 37–44
Oruto Multicenter Transplant Study Group (1985) A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313: 337–342
Kahana L, Baxter J (1987) OKT3 rescue in refractory renal rejection. Nephron 46: 34–40
Colona JO, Goldstein LI, Brems JJ, Vargas JH, Brill JE, Berquist W, Hiatt JR, Busuttil RW (1987) A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroid-resistant liver transplant rejection. Arch Surg 122: 1120–1123
Ackermann JR (1988) Prophylactic use of OKT3 in renal transplantation: part of a prospective randomized multicenter trial. Transplant Proc 20: 242–244
Kreis H, Chkoff N, Chatenoud L (1989) A randomized trial comparing the efficacy of OKT3 used to prevent or to treat rejection. Transplant Proc 21: 3
Norman DJ, Shield CF, Barry J (1988) Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection. Am J Kidney Dis 11: 107–110
Vigeral P, Chkoff N, Chatenoud L, Campos H, Lacombe M, Droz D, Goldstein G, Bach JF, Kreis H (1986) Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent. Transplantation 41: 730–733
Norman DJ, Leone MR (1991) The role of OKT3 in clinical transplantation. Pediatr Nephrol 5: 130–136
Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Bach JF (1983) Immunologic follow-up of renal allograft recipients treated prophylactically by OKT3 alone. Transplant Proc 15: 643–645
Schroeder TJ, Frist MR, Mansour ME, Hurtubisse PE, Hariharan S, Ryckman FC, Munda R, Melvin DB, Penn I, Ballistreri WF, Alexander JW (1990) Antimurine antibody formation following OKT3 therapy. Transplantation 49: 48–51
Mayes JT, Thistlethwaite JR, Stuart JJ, Buckingham MR, Stuart FP (1988) Reexposure to OKT3 in renal allograft recipients. Transplantation 45: 349–353
Norman DJ, Shield CF, Henell KR, Kimball J, Barry JM, Bennett WM, Leone M (1988) Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection. Transplantation 46: 523–529
Hricik DE, Mayes JT, Shulak JA (1990) Inhibition of anti-OKT3 antibody generation by ciclosporine: results of a prospective randomized trial. Transplantation 50: 237–240
Jaffers GJ, Fuller T, Cosimi AB, Russell PS, Win HJ, Colvin RB (1986) Monoclonal antibody therapy: antiidiotypic and non-antiidiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 41: 572–578
Leone MR, Barry JM, Alexander SR, Melvin T, Striegel J, Henell KR, Kimball J, Funnell MB, Goldstein G, Norman DJ (1990) Monoclonal antibody OKT3 therpay in pediatric kidney transplant recipients. J Pediatr 116: S86-S91
Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Batch JF (1986) Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3 J Immunol 137: 830–838
Niaudet P, Murcia I, Jean G, Broyer M (1990) Essai comparatif de l'OKT3 et du sérum antilymphocytaire dans le traitement préventif du rejet après transplantation rénale chez l'enfant. Ann Pediatr (Paris) 37: 83–85
Schroeder T, Superina R, Ettinger R (1992) Monoclonal antibody therapy in pediatric transplantation. Transplant Proc 24: S1-S10
Legendre C, Kreis H, Bach JF, Chatenoud L (1992) Prediction of successful allograft rejection retreatment with OKT3. Transplantation 53: 87–90
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Niaudet, P., Jean, G., Broyer, M. et al. Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients. Pediatr Nephrol 7, 263–267 (1993). https://doi.org/10.1007/BF00853215
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00853215